CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that clinical data from its allogeneic BCMA-targeted CAR T-cell product candidate, CT0596, for the treatment of relapsed/refractory multiple myeloma (R/R MM) was presented in a poster at the 67th American Society of Hematology (ASH) Annual Meeting. The poster […]

The Ohio State University’s Caleb Downs Named Winner of Lott IMPACT Trophy Presented by Allied Universal

The Ohio State University's Caleb Downs Named Winner of Lott IMPACT Trophy Presented by Allied Universal GlobeNewswire December 08, 2025 NEWPORT BEACH, Calif., Dec. 07, 2025 (GLOBE NEWSWIRE) — Caleb Downs from The Ohio State University has been named winner of the Lott IMPACT(R) Trophy presented by Allied Universal(R). A junior safety for the Buckeyes,

Median PFS Trending Beyond One Year: Leads Biolabs’ LBL-034 Showcases Breakthrough Clinical Data in Oral Presentation at the 2025 ASH Annual Meeting

From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology (“ASH”) was held in Orlando, Florida, USA. Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company”, Stock Code: 9887.HK) delivered an oral presentation on the opening day of the conference featuring the Phase I/II clinical results of LBL-034,

Traveloka and Singapore Tourism Board launch regional campaign to inspire spontaneous weekend getaways to Singapore

Traveloka, Southeast Asia's leading travel platform, and the Singapore Tourism Board (STB) strengthen their partnership with the launch of a new regional marketing campaign targeting young travellers titled 'A World of Experiences Await'. The initiative aims to position Singapore as a preferred short-haul destination for travellers and repeat visitors seeking spontaneous and convenient getaways from

Agoda Unveils 2026 Travel Outlook Report: Key Trends for Industry Partners to Capitalize on the Year Ahead

With interest in secondary destinations on the rise, expanding infrastructure and growing access to technology, opportunities await the industry in 2026 Digital travel platformAgoda unveils its 2026 Travel Outlook Report, highlighting data-driven trends set to influence travel across Asia in the next year. Drawing on a survey of Agoda customers in key Asia-Pacific markets, the

OPay Appoints Former Citigroup Managing Director James Perry as CFO

SINGAPORE , Dec. 07, 2025 (GLOBE NEWSWIRE) — OPay, a leader in emerging market digital banking headquartered in Singapore, has appointed James Perry as Chief Financial Officer (CFO), effective December 1, 2025. James Perry will oversee OPay's financial strategy planning, capital structure management, and investor relations, reporting to the CEO. James Perry holds a bachelor's

OPay Appoints Former Citigroup Managing Director James Perry as CFO

OPay Appoints Former Citigroup Managing Director James Perry as CFO GlobeNewswire December 08, 2025 SINGAPORE , Dec. 07, 2025 (GLOBE NEWSWIRE) — OPay, a leader in emerging market digital banking headquartered in Singapore, has appointed James Perry as Chief Financial Officer (CFO), effective December 1, 2025. James Perry will oversee OPay's financial strategy planning, capital

IASO Bio Presents Updated Results for Equecabtagene Autoleucel in High-Risk Newly Diagnosed Multiple Myeloma Patients at 2025 ASH

IASO Biotechnology (“IASO Bio”), a commercial-stage biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of novel cell therapies and biologics for hematologic malignancies and autoimmune diseases, announced the oral presentation of updated clinical data for its independently developed, fully human BCMA-targeted CAR-T cell therapy product, Equecabtagene Autoleucel (Eque-cel), for the treatment of transplant-ineligible

MSP Recovery, Inc. Announces Conclusion of SEC Investigation: No Intention to Recommend Enforcement Action Against the Company, its CEO, John H. Ruiz, or its Officers

MIAMI, FLORIDA / ACCESS Newswire / December 7, 2025 / MSP Recovery, Inc. (NASDAQ:MSPR) (the "Company"), a Medicare, Medicaid, commercial, and secondary payer reimbursement recovery and technology leader, announces that the staff of the U.S. Securities and Exchange Commission ("SEC") has informed the Company that it has concluded its investigation relating to MSP Recovery, Inc.,

Scroll to Top